BRIDGE

BRIDGE

SUPPORTING

  • Ongoing phase 2 study with up to 25 patients
  • Open-label, single-arm study for patients with reduced renal function
  • Positioning study to show melflufen’s treatment profile within this patient group
  • Started in Q3 2018, with last patient in (LPI) expected in H1 2021